EMBARK The EMBARK clinical trial is to assess the safety and effectiveness of the FDA approved drugs enzalutamide (Xtandi) and leuprolide (Lupron) in combination and compared to each drug alone in patients with prostate cancer progressing (but not spread to other parts of the body) after being treated with surgery or radiation or both. Enzalutamide is not currently approved by the FDA for this type of cancer. Patients who participate in the EMBARK trial are randomly (by chance) assigned to either a group to receive enzalutamide plus leuprolide or to a group which will receive only enzalutamide or leuprolide plus placebo. Leuprolide is the standard of care for patients with high-risk non-metastatic prostate cancer. EMBARK is a phase 3 clinical trial which will enroll 1860 patients. The trial began in 2014 and the primary completion date is 2020.
Possible patient benefitsinclude increasing the time before prostate cancer spreads (progresses) and metastasizes, and prolonging life.
If you are interested in this trial you can take these actions: